RBC Capital analyst Conor McNamara initiated coverage of Natera (NTRA) with an Outperform rating and $251 price target The firm says Natera is the ...

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

BTIG analyst Mark Massaro maintained a Buy rating on Natera (NTRA – Research Report) today and set a price target of $190.00. The company’s ...

While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Natera (NTRA – Research Report), with a price target ...

Shares of Natera stock opened at $140.66 on Wednesday. The stock has a market cap of $19.02 billion, a price-to-earnings ratio of -79.92 and a beta of 1.80. The company has a debt-to-equity ratio ...

Shares of Natera, Inc. (NASDAQ:NTRA – Get Free Report) saw strong trading volume on Tuesday after Morgan Stanley raised their price target on the stock from $176.00 to $185.00. Morgan Stanley ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center ...